What is NeRRe Therapeutics?
Founded in 2012 as a spin-out from GSK, NeRRe Therapeutics operates at the intersection of neurobiology and respiratory health. The company is primarily focused on the development of orvepitant, a novel therapeutic candidate designed to treat chronic cough associated with idiopathic pulmonary fibrosis (IPF). By targeting the neurokinin-1 receptor, NeRRe aims to provide a breakthrough intervention for patients suffering from terminal lung conditions where current standard-of-care options remain insufficient. The company's operational model is built upon a foundation of rigorous clinical development and strategic partnerships with leading life sciences investors, positioning it as a key player in the development of specialized therapeutics for rare diseases.
How much funding has NeRRe Therapeutics raised?
NeRRe Therapeutics has raised a total of $36.3M across 2 funding rounds:
Series A
$8.1M
Series B
$28.2M
Series A (2012): $8.1M, investors not publicly disclosed
Series B (2017): $28.2M led by Fountain Healthcare Partners, Forbion, OrbiMed, Novo A/S, and Advent Life Sciences
Key Investors in NeRRe Therapeutics
Fountain Healthcare Partners
A venture fund providing risk capital and deep expertise to entrepreneurs in the life sciences sector, focusing on specialty pharma and biopharmaceuticals.
Forbion
A global life sciences venture capital firm with a strong track record of guiding biotech companies from early-stage development through to clinical maturity.
OrbiMed
A specialized healthcare investment firm managing capital across biopharmaceuticals and medical devices, known for its hands-on approach to operational optimization.
What's next for NeRRe Therapeutics?
With the successful deployment of its recent capital, NeRRe Therapeutics is poised to advance its lead asset through critical clinical milestones. The strategic focus remains on validating the efficacy of orvepitant in larger patient cohorts, potentially establishing a new therapeutic paradigm for cough hypersensitivity. As the company transitions through its current lifecycle stage, the emphasis will likely shift toward regulatory engagement and the optimization of commercialization pathways. The continued support from its high-profile investor syndicate provides the necessary runway to navigate the complexities of late-stage clinical trials and potential market entry, ensuring that NeRRe remains at the forefront of innovation in the treatment of debilitating respiratory disorders.
See full NeRRe Therapeutics company page
